INCY - Incyte ending phase 3 program evaluating myelofibrosis candidate parsaclisib
- Incyte ( NASDAQ: INCY ) said it would end a phase 3 program examining its myelofibrosis candidate parsaclisib with Jakafi (ruxolitinib) after an interim analysis showed the study was unlikely to meet its primary endpoint.
- The primary endpoint of the LIMBER-304 study was the ratio of patients achieving targeted reduction in spleen volume as measured by magnetic resonance imaging or computed tomography.
- Shares are down 4% in after-hours trading.
- The recommendation to end the study came from an independent data monitoring committee and was not due to safety concerns .
- The trial was examining whether adding parsaclisib would help individuals with an inadequate response to Jakafi.
- Read why Seeking Alpha contributor Robert Honeywill calls Incyte ( INCY ) a buy.
For further details see:
Incyte ending phase 3 program evaluating myelofibrosis candidate parsaclisib